pharmaphorum April 19, 2024
Cerevel Therapeutics’ Parkinson’s disease therapy tavapadon has shown efficacy in a phase 3 trial, reinforcing its blockbuster potential and no doubt delighting AbbVie, which has agreed to buy the company in an $8.7 billion deal.
Tavapadon is just one part of a pipeline that AbbVie chief executive Rick Gonzalez said had “multibillion-dollar sales potential” when the deal was announced last year, alongside other late-stage programmes like schizophrenia therapy emraclidine.
That confidence now seems to have been well placed. The dopamine D1/D5 partial agonist has met its main objective in the pivotal TEMPO-3 trial as an add-on to mainstay Parkinson’s treatment levodopa, achieving a statistically significant reduction in ‘on’ time – when symptoms are under control – compared to placebo without...
Today's Sponsors
Today's Sponsor